A Fifty-two-week Study to Evaluate the Safety of Saredutant in Adult and Elderly Patients With Depression

NCT00250653 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

365

Enrollment

INDUSTRY

Sponsor class

Conditions

Depressive Disorder

Interventions

DRUG: Saredutant succinate (SR48968C)

Sponsor

Sanofi